CG Oncology Inc. (CGON) Stock: Price, Forecast & Analyst Target
CG Oncology Inc. (CGON) — MoonshotScore 26/100 (Weak band), calculated Nov 18, 2026. Price $79.47 (-2.97%), as of the Nov 20, 2026 trading session; market cap $7.10B. Expected results Feb 26, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 7.21× (cash as of Sep 30, 2026) · expected results Feb 26, 2027
CG Oncology Inc. · CGON · NASDAQ · Healthcare · Biotechnology
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · CG Oncology (CGON)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but bottom-tier quality, weak growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $2M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 81.15 · Piotroski F 2
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $79.47 | |
| Change on the day | -2.97% | |
| 52-week range | $37.01–$93.95 | |
| Market capitalisation | $7.10B | — |
| Price / earnings (trailing) | -22.33 | |
| Shares traded on the day | 1.67M | |
| Beta (volatility vs the S&P 500) | 0.24 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for CG Oncology (CGON): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is CG Oncology (CGON), and what does it report?
Short answer
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. CG Oncology Inc. (CGON) is listed on NASDAQ. CG Oncology Inc. (CGON) is classified as Healthcare / Biotechnology. SEC filing business address: 3000 Pegasus Park Drive, Suite 1640, Dallas, TX, 75247. It employs 142 people and is led by Arthur Kuan. In Q3 FY2025 it reported revenue of $2M and net income of -$44M. The market values it at $7.10B.
What do the latest results show for CG Oncology (CGON)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $2M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.60M Sep 30, 2026
- Latest quarter · R&D
- $39.22M Sep 30, 2026
- Latest quarter · SG&A
- $22.96M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$63.25M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $1.60M | $39.22M | $22.96M | −$63.25M |
| Jun 30, 2026 | $1.16M | $54.66M | $28.98M | −$86.40M |
| Mar 31, 2026 | $1.08M | $43.73M | $20.78M | −$66.39M |
| Dec 31, 2025 | $2.32M | $29.96M | $17.99M | −$48.70M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.60M Nov 6, 2026
- Latest report · revenue estimate
- $547,684 Nov 6, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 6, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 6, 2026 | $1.60M | $547,684 | −$0.6400 | −$0.8341 |
| Aug 6, 2026 | $1.16M | $360,805 | −$0.9000 | −$0.6642 |
| May 8, 2026 | $1.08M | $453,034 | −$0.7100 | −$0.5800 |
| Feb 27, 2026 | $2.31M | $450,538 | −$0.5100 | −$0.6100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $2M | -$44M | -$0.57 (diluted) |
| Q4 FY2025 | $2M | -$41M | -$0.52 (diluted) |
| Q1 FY2026 | $1M | -$60M | -$0.71 (diluted) |
| Q2 FY2026 | $1M | -$79M | -$0.90 (diluted) |
What are the financial strengths and risks for CG Oncology (CGON)?
Short answer
Cash and short-term investments were $984.46M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$47.71M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway. The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 81.15 · Piotroski F 2. Trailing ratios: ROE -28.3% · ROA -18.6% · current ratio 21.70.
Data-derived red flags
- Negative return on equity (-28.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$47.71M Sep 30, 2026
- Previous quarter · operating cash flow
- −$46.41M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$47.71M | −$1.11M |
| Jun 30, 2026 | −$46.41M | −$470,000 |
| Mar 31, 2026 | −$56.94M | −$300,000 |
| Dec 31, 2025 | −$36.22M | −$10,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at CG Oncology (CGON)?
Short answer · as of
The next earnings report is expected on Feb 26, 2027. Current published price targets run low $97.00 · high $113.00 · consensus $102.50 · median $100.00 against a quoted price of $79.47 (as of Nov 20, 2026).
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Nov 14, 2025 — 11 months ago.
Checked against the records this page reads, on the dates shown above.
How does CG Oncology compare with its peers?
Short answer
CG Oncology's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.89 Nov 20, 2026 | $7.38B | 98 5-pillar Nov 18, 2026 | |
| $308.89 Nov 20, 2026 | $9.15B | 96 5-pillar Nov 18, 2026 | |
| $63.62 Nov 20, 2026 | $6.96B | 91 5-pillar Nov 18, 2026 | |
| $63.34 Nov 20, 2026 | $9.57B | 90 5-pillar Nov 18, 2026 | |
| $121.40 Nov 20, 2026 | $7.92B | 88 5-pillar Nov 18, 2026 | |
| $17.58 Nov 20, 2026 | $5.04B | 83 5-pillar Nov 18, 2026 | |
| $286.85 Nov 20, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $95.81 Nov 20, 2026 | $6.50B | 67 5-pillar Nov 18, 2026 | |
| $119.52 Nov 20, 2026 | $5.04B | 66 5-pillar Nov 18, 2026 | |
| $127.38 Nov 20, 2026 | $5.17B | 64 5-pillar Nov 18, 2026 | |
| $37.04 Nov 20, 2026 | $3.64B | 56 5-pillar Nov 18, 2026 | |
| $53.35 Nov 20, 2026 | $2.61B | 45 5-pillar Nov 18, 2026 | |
| CG Oncology (CGON) — this page | $79.47 | $7.10B | 26 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $97.00 – $113.00
- Consensus target
- $102.50
- Median target
- $100.00
Consensus record · Captured .
Measured against a quoted price of $79.47 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026
- Transactions
- 41
- Identified insiders
- 7
- Purchases
- 1
- Sales
- 11
- Other transactions
- 29
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 247 Period end Sep 30, 2026
- Previous quarter · holders
- 248 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Rtw Investments, LP | 8,514,590 |
| T. Rowe Price Investment Management, INC. | 6,726,945 |
| Decheng Capital LLC | 6,371,669 |
| Blackrock, INC. | 6,347,335 |
| Wellington Management Group Llp | 4,917,082 |
Tracked investors
Which of the 16 named investors we follow held CGON in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CGON in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about CG Oncology (CGON)?
What Investors Ask About CG Oncology (CGON) — Healthcare
These answers are editorial: 1 of these 9 answers is drawn from the CGON research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CGON?
CGON carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. CG Oncology Inc. is a clinical-stage biopharmaceutical company focused on developing bladder-sparing therapeutics for bladder cancer patients.
Is CGON a good stock to buy?
Stock Expert AI does not rate CGON buy, sell or hold. CG Oncology Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CGON stock price today?
The last price recorded for CG Oncology Inc. (CGON), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CGON price target?
The analyst consensus price target for CG Oncology Inc. (CGON), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for CGON?
The main risks for CGON include the inherent uncertainties associated with clinical-stage drug development, such as the potential for clinical trial failures or delays. Competition from existing and emerging therapies in the bladder cancer treatment landscape could impact CGON's market share.
What are the key factors to evaluate for CGON?
CG Oncology Inc. (CGON) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. This could lead to increased market penetration and revenue growth. Not financial advice.
How frequently does CGON data refresh on this page?
CGON's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CGON's recent stock price performance?
CG Oncology Inc. (CGON) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach with cretostimogene. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CGON overvalued or undervalued right now?
CG Oncology Inc. (CGON) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 1 from SEC filings and earnings calls, 74 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com